NCT05795621View on ClinicalTrials.gov

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
Thyroid Eye Disease
Interventions
BIOLOGICAL

IBI311

10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.

BIOLOGICAL

placebo

4 does of placebo for phase II; 8 does of placebo for phase III.

Trial Locations (1)

200000

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY